Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 2Genitourinary 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 20Melanoma 16Prostatic Neoplasms 15Neoplasms 15Recurrence 13Carcinoma, Non-Small-Cell Lung 13Leukemia, Myeloid, Acute 12Glioblastoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Glioma 7Breast Neoplasms 7Sarcoma 6Neuroblastoma 6Lung Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Lambert-Eaton Myasthenic Syndrome 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neuroendocrine Tumors 4Liver Neoplasms 4Hodgkin Disease 4Precancerous Conditions 3Pheochromocytoma 3

Interventions

tazemetostat 1omburtamab I-131 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Rhabdoid Tumor × Clear all
NCT05064306 2025-08-01

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Memorial Sloan Kettering Cancer Center

No longer available
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Medulloblastoma, Meningeal Neoplasms, Wilms Tumor, Neuroblastoma, Pinealoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Ipsen

No longer available
GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡